Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Apr 18 2025 | U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications Industry News In The News Industry Read More Apr 17 2025 | Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Industry News In The News Industry Read More Apr 15 2025 | New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival Industry News In The News Industry Read More Apr 10 2025 | A Novel Congestion Index for Heart Failure and the Impact of Social Isolation Among Older Adults with Advanced Heart Failure Highlighted in the April 2025 Issue of Journal of Cardiac Failure (JCF) HFSA News Journal of Cardiac Failure Press Release Read More Apr 9 2025 | Journal of Cardiac Failure Call for Papers: Focus Issue on Hemodynamics HFSA News Journal of Cardiac Failure Read More Pagination First page « First Previous page ‹ Previous … Page 14 Page 15 Page 16 Page 17 Current page 18 Page 19 Page 20 Page 21 Page 22 … Next page Next › Last page Last »
Apr 18 2025 | U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications Industry News In The News Industry Read More
Apr 17 2025 | Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Industry News In The News Industry Read More
Apr 15 2025 | New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival Industry News In The News Industry Read More
Apr 10 2025 | A Novel Congestion Index for Heart Failure and the Impact of Social Isolation Among Older Adults with Advanced Heart Failure Highlighted in the April 2025 Issue of Journal of Cardiac Failure (JCF) HFSA News Journal of Cardiac Failure Press Release Read More
Apr 9 2025 | Journal of Cardiac Failure Call for Papers: Focus Issue on Hemodynamics HFSA News Journal of Cardiac Failure Read More
